Emcure Pharmaceuticals Limited

NSEI:EMCURE Stock Report

Market Cap: ₹338.1b

Emcure Pharmaceuticals Future Growth

Future criteria checks 4/6

Emcure Pharmaceuticals is forecast to grow earnings and revenue by 19% and 11.2% per annum respectively. EPS is expected to grow by 19% per annum. Return on equity is forecast to be 22.3% in 3 years.

Key information

19.0%

Earnings growth rate

19.04%

EPS growth rate

Pharmaceuticals earnings growth16.1%
Revenue growth rate11.2%
Future return on equity22.33%
Analyst coverage

Good

Last updated20 Jul 2026

Recent future growth updates

Analysis Article • Nov 14

Emcure Pharmaceuticals Limited (NSE:EMCURE) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Emcure Pharmaceuticals Limited ( NSE:EMCURE ) last week reported its latest quarterly results, which makes it a good...
Analysis Article • May 25

Analyst Estimates: Here's What Brokers Think Of Emcure Pharmaceuticals Limited (NSE:EMCURE) After Its Yearly Report

The investors in Emcure Pharmaceuticals Limited 's ( NSE:EMCURE ) will be rubbing their hands together with glee today...

Recent updates

Narrative Update • Jun 23

EMCURE: Capacity Expansion And Governance Resolutions Will Shape Balanced Forward Outlook

Analysts have nudged their fair value estimate for Emcure Pharmaceuticals from ₹1,891.83 to ₹1,913.50, reflecting updated assumptions around slightly higher revenue growth, a marginally adjusted profit margin, and a modestly higher future P/E multiple. What’s in the News for Emcure Pharmaceuticals Emcure Pharmaceuticals plans to increase investments in domestic expansion, research and development, and manufacturing capacity, while also reviewing acquisition opportunities in India and international markets such as Europe and Canada.
Narrative Update • Jun 06

EMCURE: Governance Actions And Expansion Investments Will Shape Steady Forward Outlook

Analysts have raised their fair value estimate for Emcure Pharmaceuticals to ₹1,891.83 from ₹1,795.67, reflecting updated assumptions around discount rates, revenue growth, profit margins and a future P/E of 31.02x. What's in the News Company executives indicate plans to increase investments in domestic expansion, research and development, and manufacturing, while also scanning for acquisition opportunities in India and internationally, including Europe and Canada (source: ET, via company commentary).
Analysis Article • May 22

If EPS Growth Is Important To You, Emcure Pharmaceuticals (NSE:EMCURE) Presents An Opportunity

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Narrative Update • May 03

EMCURE: Governance Meetings And Roche Partnership Will Shape Steady Forward Outlook

Analysts have maintained their price target for Emcure Pharmaceuticals at ₹1,795.67, citing unchanged assumptions around discount rate, revenue growth, profit margin and future P/E as the basis for keeping their valuation view intact. What's in the News Board meeting scheduled for May 5, 2026, to review audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to consider a final equity dividend, if any (company filing).
Narrative Update • Apr 19

EMCURE: Upcoming Governance And Roche Agreement Will Shape Balanced Forward Outlook

Analysts have nudged their price target on Emcure Pharmaceuticals slightly higher to around ₹1,796 from about ₹1,795, citing updated assumptions for revenue growth, profit margins and a modestly lower future P/E expectation. What's in the News Emcure signed a distribution agreement with Roche for select nephrology and transplant medicines in India, covering therapies for chronic kidney disease, anemia management, and transplant care, effective April 1, 2026 (Key Developments).
Narrative Update • Apr 04

EMCURE: Upcoming Governance Decisions Will Support Future Upside Potential

Analysts have kept their fair value estimate for Emcure Pharmaceuticals steady at about ₹1,794, reflecting largely unchanged assumptions around discount rate, revenue growth, profit margin and future P/E. This signals that their core view on the stock remains consistent.
Narrative Update • Mar 21

EMCURE: Weight Management Franchise Will Support Future Upside Potential

Analysts have kept their price target for Emcure Pharmaceuticals steady at ₹1,794.83, citing essentially unchanged assumptions around the discount rate, revenue growth, profit margin, and future P/E expectations. What's in the News Emcure plans a board meeting on February 4, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025.
Narrative Update • Mar 06

EMCURE: Weight Management Launch Will Underpin Future Shareholder Value Potential

Analysts have kept their fair value estimate for Emcure Pharmaceuticals steady at about ₹1,794.83 per share, citing unchanged assumptions for discount rate, revenue growth, profit margin and future P/E, which together support an unchanged price target narrative. What's in the News Emcure Pharmaceuticals has scheduled a board meeting on February 4, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).
Narrative Update • Feb 19

EMCURE: Weight Management Launch Will Support Stronger Long Term Outlook

Analysts have nudged their price target on Emcure Pharmaceuticals higher from ₹1,688.50 to about ₹1,794.83, citing updated assumptions around discount rate, revenue growth, profit margin, and future P/E, which together support a slightly richer valuation framework. What's in the News Board meeting scheduled for Feb 4, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (company filing).
Analysis Article • Feb 06

Here's Why We Think Emcure Pharmaceuticals (NSE:EMCURE) Might Deserve Your Attention Today

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Narrative Update • Feb 05

EMCURE: Weight Management Launch And Alliance Will Shape Balanced Outlook

Analysts have raised their fair value estimate for Emcure Pharmaceuticals from ₹1,652.50 to ₹1,688.50, reflecting updated assumptions related to revenue growth, profit margins and a slightly lower future P/E multiple. What's in the News Emcure Pharmaceuticals has scheduled a board meeting on February 4, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Board Meeting).
Analysis Article • Nov 14

Emcure Pharmaceuticals Limited (NSE:EMCURE) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Emcure Pharmaceuticals Limited ( NSE:EMCURE ) last week reported its latest quarterly results, which makes it a good...
Analysis Article • Sep 27

These 4 Measures Indicate That Emcure Pharmaceuticals (NSE:EMCURE) Is Using Debt Reasonably Well

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
User avatar
New Narrative • Aug 10

Expansion In Chronic Therapies And Emerging Markets Will Thrive

Expansion in chronic therapies, specialty areas, and emerging markets is driving sustained revenue growth and broader international diversification.
Analysis Article • May 25

Analyst Estimates: Here's What Brokers Think Of Emcure Pharmaceuticals Limited (NSE:EMCURE) After Its Yearly Report

The investors in Emcure Pharmaceuticals Limited 's ( NSE:EMCURE ) will be rubbing their hands together with glee today...
Analysis Article • May 16

Emcure Pharmaceuticals Limited's (NSE:EMCURE) P/E Is On The Mark

Emcure Pharmaceuticals Limited's ( NSE:EMCURE ) price-to-earnings (or "P/E") ratio of 33.2x might make it look like a...
Analysis Article • Feb 15

Emcure Pharmaceuticals Limited (NSE:EMCURE) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless

The Emcure Pharmaceuticals Limited ( NSE:EMCURE ) share price has fared very poorly over the last month, falling by a...
Analysis Article • Jan 06

We Think Emcure Pharmaceuticals (NSE:EMCURE) Can Stay On Top Of Its Debt

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Earnings and Revenue Growth Forecasts

NSEI:EMCURE - Analysts future estimates and past financials data (INR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/2029129,11216,44112,94319,2944
3/31/2028117,36014,18711,70216,9897
3/31/2027104,41111,43511,00315,5367
3/31/202692,0359,2443,9599,435N/A
12/31/202588,5018,699N/AN/AN/A
9/30/202584,4927,9313,4457,477N/A
6/30/202581,8147,442N/AN/AN/A
3/31/202578,9606,8134,4488,517N/A
12/31/202475,5116,075N/AN/AN/A
9/30/202472,5615,6735,6219,032N/A
6/30/202469,1725,119N/AN/AN/A
3/31/202466,5834,9827,90110,972N/A
12/31/202364,8425,398N/AN/AN/A
9/30/202364,1396,0037,43911,120N/A
6/30/202361,4645,532N/AN/AN/A
3/31/202359,8585,3203,4357,469N/A
3/31/202258,5546,6223,7127,682N/A
3/31/202150,3355,8085,5887,044N/A
3/31/202050,4868363,4575,003N/A
3/31/201947,1721,893N/A4,826N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: EMCURE's forecast earnings growth (19% per year) is above the savings rate (6.9%).

Earnings vs Market: EMCURE's earnings (19% per year) are forecast to grow faster than the Indian market (16.4% per year).

High Growth Earnings: EMCURE's earnings are forecast to grow, but not significantly.

Revenue vs Market: EMCURE's revenue (11.2% per year) is forecast to grow faster than the Indian market (11% per year).

High Growth Revenue: EMCURE's revenue (11.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: EMCURE's Return on Equity is forecast to be high in 3 years time (22.3%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/20 09:31
End of Day Share Price 2026/07/17 00:00
Earnings2026/03/31
Annual Earnings2026/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Emcure Pharmaceuticals Limited is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kunal RanderiaAxis Capital Limited
Foram ParekhBOB Capital Markets Ltd.
null nullBOB Capital Markets Ltd.